Sutro Biopharma Inc (STRO)
4.245
+0.36
(+9.13%)
USD |
NASDAQ |
May 07, 16:00
4.245
0.00 (0.00%)
After-Hours: 20:00
Sutro Biopharma Cash from Financing (TTM): 137.55M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 137.55M |
September 30, 2023 | 152.90M |
June 30, 2023 | 188.49M |
March 31, 2023 | 56.31M |
December 31, 2022 | 48.31M |
September 30, 2022 | 36.60M |
June 30, 2022 | 7.714M |
March 31, 2022 | 2.19M |
December 31, 2021 | 3.256M |
September 30, 2021 | 147.60M |
June 30, 2021 | 163.91M |
Date | Value |
---|---|
March 31, 2021 | 255.37M |
December 31, 2020 | 269.25M |
September 30, 2020 | 122.61M |
June 30, 2020 | 104.21M |
March 31, 2020 | 11.98M |
December 31, 2019 | -4.184M |
September 30, 2019 | 85.45M |
June 30, 2019 | 136.75M |
March 31, 2019 | 170.34M |
December 31, 2018 | 170.78M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.184M
Minimum
Dec 2019
269.25M
Maximum
Dec 2020
101.38M
Average
104.21M
Median
Jun 2020
Cash from Financing (TTM) Benchmarks
AnaptysBio Inc | -59.30M |
ABVC BioPharma Inc | 3.919M |
Reviva Pharmaceuticals Holdings Inc | 33.17M |
Flora Growth Corp | 3.15M |
Journey Medical Corp | -4.804M |